This website requires certain cookies to work and uses other cookies to help you have the best experience. By visiting this website, certain cookies have already been set, which you may delete and block. By closing this message or continuing to use our site, you agree to the use of cookies. Visit our updated privacy and cookie policy to learn more.
This Website Uses Cookies By closing this message or continuing to use our site, you agree to our cookie policy. Learn MoreThis website requires certain cookies to work and uses other cookies to help you have the best experience. By visiting this website, certain cookies have already been set, which you may delete and block. By closing this message or continuing to use our site, you agree to the use of cookies. Visit our updated privacy and cookie policy to learn more.
MARLBOROUGH, MA—Boston Scientific Corp. has agreed to buy rival BTG Corp. for $4.2 billion to expand its offering of medical devices to treat cancer and other disorders. Boston Scientific makes stents that hold open damaged blood vessels. BTG makes medical technology for physicians, such as cryoablation products to freeze and destroy diseased cells, and radiotherapy that delivers radiation straight to tumors.